113 related articles for article (PubMed ID: 12892898)
1. G-CSF immunotherapy for treatment of acute disseminated murine melioidosis.
Powell K; Ulett G; Hirst R; Norton R
FEMS Microbiol Lett; 2003 Jul; 224(2):315-8. PubMed ID: 12892898
[TBL] [Abstract][Full Text] [Related]
2. Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model.
Feterl M; Govan B; Engler C; Norton R; Ketheesan N
Int J Antimicrob Agents; 2006 Nov; 28(5):460-4. PubMed ID: 17046208
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary Delivery of Ceftazidime for the Treatment of Melioidosis in a Murine Model.
Ruiz SI; Bowen LE; Bailey MM; Berkland C
Mol Pharm; 2018 Mar; 15(3):1371-1376. PubMed ID: 29363975
[TBL] [Abstract][Full Text] [Related]
4. Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model.
Ulett GC; Norton RE; Hirst RG
Pathology; 1999 Aug; 31(3):264-7. PubMed ID: 10503275
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.
Propst KL; Troyer RM; Kellihan LM; Schweizer HP; Dow SW
Antimicrob Agents Chemother; 2010 May; 54(5):1785-92. PubMed ID: 20176901
[TBL] [Abstract][Full Text] [Related]
6. Use of a low-dose steroid as an adjunct in the treatment, in mice, of severe sepsis caused by Burkholderia pseudomallei.
Panomket P; Chetchotisakd P; Sermswan RW; Pannengpetch P; Wongratanacheewin S
Ann Trop Med Parasitol; 2009 Oct; 103(7):635-46. PubMed ID: 19825285
[TBL] [Abstract][Full Text] [Related]
7. Induction of multiple chemokine and colony-stimulating factor genes in experimental Burkholderia pseudomallei infection.
Barnes JL; Ulett GC; Ketheesan N; Clair T; Summers PM; Hirst RG
Immunol Cell Biol; 2001 Oct; 79(5):490-501. PubMed ID: 11564157
[TBL] [Abstract][Full Text] [Related]
8. A comparison of antibiotic regimens in the treatment of acute melioidosis in a mouse model.
Ulett GC; Hirst R; Bowden B; Powell K; Norton R
J Antimicrob Chemother; 2003 Jan; 51(1):77-81. PubMed ID: 12493790
[TBL] [Abstract][Full Text] [Related]
9. Potential of repurposing chloroquine as an adjunct therapy for melioidosis based on a murine model of Burkholderia pseudomallei infection.
Ganesan N; Embi N; Hasidah MS
Trop Biomed; 2020 Jun; 37(2):303-317. PubMed ID: 33612800
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis.
Cheng AC; Stephens DP; Anstey NM; Currie BJ
Clin Infect Dis; 2004 Jan; 38(1):32-7. PubMed ID: 14679445
[TBL] [Abstract][Full Text] [Related]
11. Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosis.
Cummings JE; Lunde CS; Alley MRK; Slayden RA
PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011795. PubMed ID: 38011278
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factor and an in vitro whole blood model of melioidosis.
Cheng AC; Dasari P; Currie BJ
Eur J Clin Microbiol Infect Dis; 2004 Mar; 23(3):205-7. PubMed ID: 14986161
[TBL] [Abstract][Full Text] [Related]
13. Formulation and Characterization of Nanocluster Ceftazidime for the Treatment of Acute Pulmonary Melioidosis.
Ruiz SI; El-Gendy N; Bowen LE; Berkland C; Bailey MM
J Pharm Sci; 2016 Nov; 105(11):3399-3408. PubMed ID: 27639659
[TBL] [Abstract][Full Text] [Related]
14. Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia.
Crowe A; McMahon N; Currie BJ; Baird RW
Int J Antimicrob Agents; 2014 Aug; 44(2):160-2. PubMed ID: 24924662
[TBL] [Abstract][Full Text] [Related]
15. Gamma interferon supplementation for melioidosis.
Koh GC; Limmathurotsakul D
Antimicrob Agents Chemother; 2010 Oct; 54(10):4520; author reply 4520-1. PubMed ID: 20852188
[No Abstract] [Full Text] [Related]
16. A model of immunity to Burkholderia pseudomallei: unique responses following immunization and acute lethal infection.
Ulett GC; Labrooy JT; Currie BJ; Barnes JL; Ketheesan N
Microbes Infect; 2005; 7(11-12):1263-75. PubMed ID: 16027024
[TBL] [Abstract][Full Text] [Related]
17. Experimental Persistent Infection of BALB/c Mice with Small-Colony Variants of Burkholderia pseudomallei Leads to Concurrent Upregulation of PD-1 on T Cells and Skewed Th1 and Th17 Responses.
See JX; Samudi C; Saeidi A; Menon N; Choh LC; Vadivelu J; Shankar EM
PLoS Negl Trop Dis; 2016 Mar; 10(3):e0004503. PubMed ID: 26974441
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ceftazidime in a murine model following a lethal aerosol exposure to Burkholderia pseudomallei.
Pfefferle DA; Hackett M; Anderson MS; Gibbs S; Henning LN; Joice AC; Meister GT
Sci Rep; 2023 Mar; 13(1):4047. PubMed ID: 36899021
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3β inhibition improved survivability of mice infected with Burkholderia pseudomallei.
Tay TF; Maheran M; Too SL; Hasidah MS; Ismail G; Embi N
Trop Biomed; 2012 Dec; 29(4):551-67. PubMed ID: 23202600
[TBL] [Abstract][Full Text] [Related]
20. Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei.
Wilson WJ; Afzali MF; Cummings JE; Legare ME; Tjalkens RB; Allen CP; Slayden RA; Hanneman WH
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005065. PubMed ID: 27792775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
